Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adipose-derived allogeneic mesenchymal stem cells (IIS-FJD)
- Development stage
- Phase 2
- Lead developer
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Laparoscopic
01
Overview
Adipose-derived allogeneic mesenchymal stem cells (adAMSCs) are an investigational cell therapy developed by the Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD) for the treatment of Crohn's disease, specifically targeting single inflammatory stenosis. These cells are harvested from the adipose tissue of healthy donors and are utilized for their potent immunomodulatory and anti-inflammatory properties. In clinical applications, such as the MEIC trial, the cells are administered via a laparoscopic procedure directly into the perilesional adipose tissue of the affected intestinal segment. The therapeutic rationale is based on the cells' capacity to secrete anti-inflammatory cytokines and growth factors, which aim to reduce local inflammation and potentially reverse or prevent the progression of fibrotic strictures in patients with Crohn's disease.
- Other names
- Allogeneic adipose-derived mesenchymal stem cellsFat-derived mesenchymal allogenic mesenchymal troncal cellsadAMSC (IIS-FJD)
Beyond the preview
Go deeper on Adipose-derived allogeneic mesenchymal stem cells (IIS-FJD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adipose-derived allogeneic mesenchymal stem cells (IIS-FJD).